For the most aggressive breast cancers, options remain rare and often toxic. A team from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has just tested an original strategy: a double attack in the form of “smart bombs” which slowed triple negative breast cancer tumors and their metastases in preclinical models.
In this study published on August 18, 2026 in Cell Reports Medicinethe researchers associated a
antibody-drug targeting CD276 (CD276-DM1) and a mitochondrial gene therapy called
cmLumiOpto. “This study suggests a possible new way to fight triple negative breast cancer by combining a targeted ‘smart bomb’ drug with a treatment that shuts down cancer cells’ energy factories“, says Xiaoguang “Margaret” Liu, lead author of the study and member of the OSUCCC – James Translational Therapies Program.
Two “smart bombs” to hit triple negative breast cancer
Triple negative breast cancer represents approximately 10 to 15% of breast cancers, without hormonal receptors or HER2, which deprives often young patients of many targeted therapies. Chemotherapy remains the mainstay and relapses are common in the first three years after diagnosis, even after treatment. But according to Tanvi Varadkar’s team, more than 70% of triple negative tumors express the protein CD276 (B7‑H3)although it is found very rarely in healthy tissues.
This marker serves as an entry point for an antibody conjugate (ADC): an anti-CD276 antibody linked to a potent cytotoxic agent, mertansine (DM1). In animal models, this CD276-DM1 has already strongly reduced tumor mass with limited systemic toxicity. CD276 also plays a role as an immune brake, the same targeting could theoretically help the immune system to regain control.
What the CD276‑DM1 + cmLumiOpto combination showed in the laboratory
The second “bomb” is cmLumiOpto, a gene therapy designed to concentrate in cancer cells and cause the mitochondria, the structures that produce energy, to collapse there. In previous preclinical models, cmLumiOpto reduced tumor burden in triple-negative breast cancer xenografts by more than 90%, but again without completely eliminating the disease.
The researchers therefore combined the two approaches. In three triple-negative breast cancer cell lines, CD276-DM1 alone still left 18 to 30% viable cells, and cmLumiOpto alone left about 50%. The association left only 8 to 12% of living cells. According to measurements of oxygen consumed, the duo reduced mitochondrial respiration much more than either treatment alone, which argues in favor of a joint attack on the structure of the tumor and its “energy engine”.
Preclinical only: what is missing before a human trial
In mouse models of triple-negative breast cancer lung metastases, CD276-DM1 or cmLumiOpto alone already reduced tumor burden. But together, the two treatments left the lungs almost unharmed, with only rare small residual foci. In patient-derived tumor models, the combination suppressed tumor growth by 95 to 100%, while preserving animal weight and without visible organ damage on histological analysis, according to data reported in Cell Reports Medicine.
Xiaoguang “Margaret” Liu adds: “These results constitute a first step. If this approach is confirmed in laboratory studies and clinical trials, it could lead to a treatment that is more effective and has fewer side effects than current options.“. In a context where triple negative breast cancer relapses after initial treatment in more than 50% of patients and where 5-year survival falls to 11% at advanced stages, this type of avenue necessarily attracts attention.
The authors, however, remain cautious. Mouse models do not reflect the full complexity of human cancers, and it remains to define the doses, the rate of administration, long-term tolerance or even the risk of resistance. “The results obtained with lower doses warrant further study, as reducing the amount of treatment could help limit dose-related side effects.“, specifies Lufang Zhou, co-senior author, professor of surgery and biomedical engineering and member of the OSUCCC – James cancer biology research program. Before considering a phase 1 trial, the team is still planning regulatory toxicology studies in mice and non-human primates, as well as the search for an industrial partner for this double “smart bomb” platform.